




ReproCyc ParvoFLEX®



Innovative, Efficacious, Safe and Flexible

ReproCyc ParvoFLEX® provides safe, efficacious protection for healthy sows and gilts 6 months of age or older against reproductive failure caused by porcine parvovirus (PPV).1,2

Innovative \\ \(\) \(



REPROCYC PARVOFLEX uses the latest technology for production, in which the key immunogenic PPV protein (VP2) is produced in a non-pathogenic baculovirus expression system and forms antigenic, virus-like particles (VLPs). With the same amount of antigen, VLPs have been shown to deliver a higher immunogenic response compared to inactivated virus used in conventional vaccines.3

REPROCYC PARVOFLEX includes the proprietary ImpranFLEX® adjuvant, an aqueousbased (non-oil) polymer adjuvant that improves the immune response of the vaccine within gilts and sows, resulting in faster, long-lasting disease protection.

Efficacious



REPROCYC PARVOFLEX utilizes the more recent PPV strain 27a, which provides a broad spectrum of protection against PPV field strains, and significantly reduces reproductive failure caused by PPV when administered to sows and gilts prior to breeding.^{2,4}

Safe



REPROCYC PARVOFLEX is safe to administer to healthy sows at any stage of gestation and gilts 6 months of age or older.1

In a field safety study that examined the safety of REPROCYC PARVOFLEX, few adverse events were recorded overall, and none was determined to be vaccine related.1

Flexible \(\)



REPROCYC PARVOFLEX supports mass-vaccination protocols in breeding herds.¹

In farms that are porcine reproductive and respiratory syndrome (PRRS) positive, producers can use FLEX ParvoPRRS[®], which combines the safety and efficacy of REPROCYC PARVOFLEX with Ingelvac PRRSFLEX® MLV in one vaccine.

Dosage and Administration


Shake well before use. Using aseptic technique, administer a single 2-mL dose by intramuscular injection. Administer a second intramuscular dose three weeks later. For more information on revaccination frequency, consult your veterinarian.


ReproCyc ParvoFLEX® Study Results

REPROCYC PARVOFLEX significantly reduces reproductive failure caused by PPV, as demonstrated by the results of a vaccination-challenge study:²

96% of fetuses from gilts vaccinated with REPROCYC PARVOFLEX were in normal condition compared to 38% of fetuses from non-vaccinated gilts. This represents five out of 22 vaccinated gilts affected by challenge versus nine out of 10 non-vaccinated gilts affected by challenge, based on clinical condition.^{2*}


Gilts vaccinated with REPROCYC PARVOFLEX had significantly more viable fetuses per litter compared to non-vaccinated gilts, as evidenced by fetal condition and litter characteristics (size and weight of fetuses at necropsy).²





REPROCYC PARVOFLEX helps to protect the progeny against transplacental infection caused by PPV, as demonstrated by the results of a vaccination-challenge study:²


An efficacy-supporting. outcome parameter of the study was evidence of PPV in fetuses, as determined by polymerase chain reaction (PCR) testing of fetal thoracic fluid. The mean number of affected fetuses in each litter was 1.41 among the vaccinated group, compared to 11.30 in the non-vaccinated group.



REPROCYC PARVOFLEX is safe to administer to healthy sows at any stage of gestation and gilts 6 months of age or older.¹

In an observational field safety study, of the 771 sows and gilts vaccinated with REPROCYC PARVOFLEX, 676 (87.7%) were observed as healthy and experienced no adverse reactions throughout the course of the study.¹

Few adverse events (AEs) were recorded overall in the study, and none of the AEs was determined to be vaccine related.¹









ReproCyc ParvoFLEX®

REPROCYC PARVOFLEX provides safe, efficacious protection for healthy sows and gilts 6 months of age or older against reproductive failure caused by porcine parvovirus (PPV).^{1,2}

- REPROCYC PARVOFLEX is a new, innovative vaccine that uses an adjuvanted baculovirus vector platform to produce a safe, highly immunogenic and non-virucidal vaccine.
- 2 REPROCYC PARVOFLEX utilizes the more recent PPV strain 27a, which provides a broad spectrum of protection against PPV field strains and significantly reduces reproductive failure caused by PPV when administered to sows and gilts prior to breeding.^{2,4}
- 3 REPROCYC PARVOFLEX supports mass-vaccination protocols in breeding herds, and is safe to administer to healthy sows at any stage of gestation and gilts 6 months of age or older.¹

References

- ¹Data on file. Boehringer Ingelheim Animal Health USA Inc. Study #2016270.
- ² Data on file. Boehringer Ingelheim Animal Health USA Inc. Study #2013057.
- ³ Martínez C, Dalsgaard K, López de Turiso J, et al. Production of porcine parvovirus empty capsids with high immunogenic activity. *Vaccine* 1992;10(10):684–690.
- ⁴ Zeeuw E, Leinecker N, Herwig V, et al. Study of the virulence and cross-neutralization capability of recent porcine parvovirus field isolates and vaccine viruses in experimentally infected pregnant gilts. *J Gen Virol* 2007;88(Pt 2):420–427.

FLEX PARVOPRRS®, REPROCYC PARVOFLEX®, INGELVAC PRRSFLEX® and IMPRANFLEX® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-POR-0016-2022